Bridging the gap: Moving predictive and prognostic assays from research to clinical use

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1531-1539

  Williams, P Michael ^a   Lively, Tracy G ^b   Jessup, J Milburn ^b   Conley, Barbara A ^b  

^a Fairview Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCESS TO INFORMATION; ANALYTIC METHOD; ASSAY; BIOASSAY; CANCER RESEARCH; CLINICAL LABORATORY; CLINICAL PRACTICE; CLINICAL STUDY; DRUG DEVELOPMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL INFORMATION SYSTEM; MOLECULAR DIAGNOSIS; NATIONAL HEALTH ORGANIZATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTIVE ASSAY; PRIORITY JOURNAL; PROGNOSTIC ASSAY; REPRODUCIBILITY; REVIEW; STANDARDIZATION; VALIDITY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PATHOLOGY, MOLECULAR; PILOT PROJECTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; VALIDATION STUDIES AS TOPIC;

EID: 84858274873     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2203     Document Type: Review

References (58)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66. (Pubitemid 26340047)
2. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al American Society of Clinical Oncology Tumor Markers Expert Panel. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27. (Pubitemid 46631379)
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312. (Pubitemid 350232263)
4. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
5. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7.
6. The White House [homepage on the Internet]. Priorities for Personalized Medicine. Report of the President's Council of Advisors on Science and Technology. [September 2008; cited 2011 Dec 12]. Available from: http://www.whitehouse.gov/files/documents/ostp/PCAST/pcast-report-v2.pdf
7. Khleif SN, Doroshow JH, Hait WN, AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010;16:3299-318.
8. Coyle VM, Johnston PG. Genomic markers for decision making: what is preventing us from using markers? Nat Rev Clin Oncol 2010;7:90-7.
9. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 2012;18:1515-23.
10. Schilsky RL, Doroshow JH, LeBlanc M, Conley BA. Development and use of integral assays in clinical trials. Clin Cancer Res 2012;18:1540-6.
11. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, et al. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today 2010;15:88-97.
12. Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal 2011;55:869-77.
13. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, et al; Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22:499-511. (Pubitemid 40603246)
14. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312-28. (Pubitemid 43237862)
15. Cummings J, Raynaud F, Jones L, Sugar R, Dive C. Fit-for-purpose biomarker method validation for application in clinical trials of anti-cancer drugs. Br J Cancer 2010;103:1313-7.
16. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-76.
17. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-7. (Pubitemid 46050874)
18. Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov 2006;5:897-902. (Pubitemid 44660603)
19. Lathia CD, Amakye D, Dai W, Girman C, Madani S, Mayne J, et al. The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther 2009;86:32-43.
20. Cancer Diagnosis Program [homepage on the internet] [cited 2012 Feb 24]. Available from: http://www.cancerdiagnosis.nci.nih.gov/diagnostics/templates. htm.
21. Clinical Laboratory Standards Institute [homepage on the Internet]. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. 2003; Vol 23, no. 16 [cited 2012 Feb 24]. Available from: http://www.clsi.org/source/orders/free/ep6-a.pdf
22. Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 2002;198:292-9. (Pubitemid 35277379)
23. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012;31:48-56.
24. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21. (Pubitemid 24226678)
25. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335:1727-32. (Pubitemid 26399347)
26. Jessup JM, Dobbin K, Hamilton S, Thibodeau S, Redston M, Taube S, et al. Interlaboratory assay reproducibility study for loss of heterozygosity on chromosome 18 (18q LOH) in colon cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 4052).
27. Food and Drug Administration [homepage on the Internet]. FDA Device Advice [cited 2011 Sep 10]. Available from: http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/default.htm
28. National Institute of Standards and Technology [homepage on the Internet]. Definitions [cited 2011 Sep 10]. Available from: http://www.nist.gov/ srm/definitions.cfm
29. International Organization for Standardization [homepage on the Internet]. ISO/IEC 17025:2005 [cited 2011 Sep 10]. Available from: http://www.iso.org/iso/ Catalogue-detail?csnumber=39883
30. International Organization for Standardization [homepage on the Internet]. ISO Guide 34:2009 [cited 2011 Sep 10]. Available from: http://www.iso.org/iso/iso-catalogue/catalogue-tc/catalogue-detail.htm?csnumber= 50174
31. Centers for Disease Control and Prevention [homepage on the Internet]. Genetic Testing Reference Materials Coordination Program (GeT-RM) - Home. DLS - Laboratory Practice Evaluation and Genomics Branch [cited 2012 Feb 24]. Available from: http://wwwn.cdc.gov/dls/genetics/rmmaterials
32. Pratt VM, Caggana M, Bridges C, Buller AM, DiAntonio L, Highsmith WE, et al. Development of genomic reference materials for cystic fibrosis genetic testing. J Mol Diagn 2009;11:186-93.
33. Kalman L, Johnson MA, Beck J, Berry-Kravis E, Buller A, Casey B, et al. Development of genomic reference materials for Huntington disease genetic testing. Genet Med 2007;9:719-23. (Pubitemid 350287158)
34. Amos Wilson J, Pratt VM, Phansalkar A, Muralidharan K, Highsmith WE Jr, Beck JC, et al; Fragile Xperts Working Group of the Association for Molecular Pathology Clinical Practice Committee. Consensus characterization of 16 FMR1 reference materials: a consortium study. J Mol Diagn 2008;10:2-12. (Pubitemid 351184830)
35. Kalman L, Wilson JA, Buller A, Dixon J, Edelmann L, Geller L, et al. Development of genomic DNA reference materials for genetic testing of disorders common in people of Ashkenazi Jewish descent. J Mol Diagn 2009;11:530-6.
36. Pratt VM, Zehnbauer B, Wilson JA, Baak R, Babic N, Bettinotti M, et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn 2010;12:835-46.
37. Barker SD, Bale S, Booker J, Buller A, Das S, Friedman K, et al. Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing. J Mol Diagn 2009;11:553-61.
38. Centers for Disease Control and Prevention [homepage on the Internet]. Genetic Testing Reference Materials Coordination Program(GeTRM) - Home [cited 2012 Feb 24]. Available from: http://www.cdc.gov/dls/genetics/rmmaterials/ default.aspx
39. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
40. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4. (Pubitemid 34705057)
41. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7. (Pubitemid 34705058)
42. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
43. National Institute of Standards and Technology [homepage on the Internet]. Standard Reference Materials Catalog [cited 2012 Feb 24]. Available from: http://www.nist.gov/srm/upload/SRM-2011-Cat-v2-All.pdf
44. U.S. Pharmacopeial Convention [homepage on the Internet]. Standards [cited 2012 Feb 24]. Available from: http://www.usp.org/referenceStandards/
45. This is based on a Query, View and Report (QVR, http://era.nih.gov/nih- and-grantor-agencies/other/query-view-and-report.cfm) search on 12/12/2011 for active grants on QVR using the terms 'assay development' and 'molecular diagnostics' compared to grants found with 'biomarkers' alone.
46. Wilson C, Schulz S, Waldman SA. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin Pharmacol Ther 2007;81:153-5.
47. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009;11:205.
48. Food and Drug Administration [homepage on the Internet]. Device approvals and clearances, recently approved devices [cited 2012 Feb 24]. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/default.htm
49. Food and Drug Administration [homepage on the Internet]. In vitro diagnostics medical devices home page [cited 2012 Feb 24].Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ InVitroDiagnostics/default.htm.
50. Kaiser J. Cancer research. Looking for a target on every tumor. Science 2009;326:218-20.
51. Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM. Lessons learned from the Investigational Device Exemption review of Children's Oncology Group Trial AAML1031. Clin Cancer Res 2012;18:1547-54.
52. National Cancer Institute [homepage on the Internet]. Clinical Assay Development Program (CADP) [cited 2012 Feb 24]. Available from: http://cadp.cancer.gov/
53. Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, et al. Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res 2008;14:3699-705.
54. Lim MD, Dickherber A, Compton CC. Before you analyze a human specimen, think quality, variability, and bias. Anal Chem 2011;83:8-13.
55. Stewart AK, McNamara E, Gay EG, Banasiak J, Winchester DP. The Rapid Quality Reporting System - a new quality of care tool for CoC-accredited cancer programs. J Registry Manag 2011;38:61-3.
56. Patel AA, Gupta D, Seligson D, Hattab EM, Balis UJ, Ulbright TM, et al Shared Pathology Informatics Network. Availability and quality of paraffin blocks identified in pathology archives: a multi-institutional study by the Shared Pathology Informatics Network (SPIN). BMC Cancer 2007;7:37.
57. Glass A, Taube S, McMurry A, Eddy C, La Chance PA, McShane L, et al. C-C4-02: Using a natural language processor to remove all elements of personal health information (PHI) to de-identify clinical annotations for the Specimen Retrieval System (SRS). Clin Med Res 2011;9:170.
58. National Cancer Institute [homepage on the Internet]. Office of Biorepositories and Biospecimen Research [cited 2012 Feb 24]. Available from: http://biospecimens.cancer.gov/default.asp